Hydofon

Hydofon, containing hydromorphone hydrochloride, is an opioid analgesic marketed in the European Union. It is supplied in oral tablet form, with strengths that meet EU regulatory standards, and is intended for prescription use under medical supervision. The product is manufactured under GMP and distributed by authorized pharmacies in EU member states. Hydofon is a Schedule II controlled substance because of dependence risk and is subject to strict prescribing rules.

Hydofon is prescribed for the management of moderate to severe pain when alternative analgesics are insufficient or not tolerated. It is commonly used in postoperative settings, cancer-related pain, and in patients requiring opioid rotation. - Acute postoperative pain - Cancer-related pain - Severe chronic pain unresponsive to non‑opioid analgesics - Pain requiring opioid rotation or breakthrough dosing - Situations where rapid analgesia is needed under close supervision

Hydromorphone may cause a range of adverse reactions, varying in frequency and severity. Common: - Constipation - Nausea - Drowsiness - Dizziness - Dry mouth - Mild itching Serious: - Respiratory depression - Severe hypotension - Acute opioid intoxication - Allergic reactions such as rash or angioedema

When prescribing Hydofon, clinicians should evaluate several safety factors to minimize risk. - Assess patient’s respiratory function before initiating therapy. - Use the lowest effective dose and limit duration to reduce dependence risk. - Avoid use in patients with known hypersensitivity to hydromorphone or other opioids. - Caution in individuals with head injury, increased intracranial pressure, or severe hepatic impairment. - Monitor for signs of sedation, confusion, or respiratory compromise, especially in the elderly. - Educate patients about proper storage and disposal to prevent misuse.

Hydofon can interact with other medications, potentially altering its safety profile. Avoid: - Concurrent use with other central nervous system depressants (e.g., benzodiazepines, barbiturates, alcohol) due to additive respiratory depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may increase hydromorphone plasma levels. - MAO inhibitors within 14 days, as they can precipitate severe reactions. Use with caution: - CNS stimulants (e.g., antidepressants, antipsychotics) that may alter opioid effects. - Diuretics and antihypertensives, which can enhance hypotensive effects. - Other opioids, requiring careful dose adjustment to avoid overdose.